SCHEDULE: VTV Therapeutics Secures $25M Private Placement

VTV Therapeutics Inc. has entered into a securities purchase agreement for a private placement totaling $25 million, involving Samsara BioCapital funds.

Summary

• VTV Therapeutics Inc. entered into a securities purchase agreement on August 29, 2025, for a private placement with institutional accredited investors, including Samsara LP and Samsara Opportunity Fund.
• The private placement involves the issuance of 682,018 shares of Class A common stock and Pre-Funded Warrants to purchase 4,561,714 shares, along with Common Warrants to purchase 5,243,732 shares.
• The purchase price for a unit of one share and an accompanying Common Warrant was $15.265, and for a unit of one Pre-Funded Warrant and an accompanying Common Warrant was $15.255.
• In the initial closing on September 3, 2025, Samsara LP purchased Pre-Funded Warrants for 655,523 shares and received 655,523 Common Warrants for $10.0 million, funded by working capital.
• Samsara Opportunity Fund subscribed to purchase 106,000 shares and Pre-Funded Warrants to purchase 877,214 shares, with accompanying Common Warrants to purchase 983,214 shares, for an additional $15.0 million in a final closing expected within 20 calendar days of the initial closing.
• Samsara BioCapital, L.P. and Samsara BioCapital GP, LLC beneficially own 339,157 shares, representing 9.9% of the Class A common stock.
• Srinivas Akkaraju beneficially owns 343,223 shares, also representing 9.9% of the Class A common stock.
• The beneficial ownership percentages are calculated based on 2,617,215 shares outstanding as of August 12, 2025, plus shares issued in the private placement and shares issuable from warrants and stock options.

Sentiment

Score: 7

Explanation: The filing reports a successful capital raise for VTV Therapeutics, which is a positive for funding operations and clinical trials. The involvement of institutional investors like Samsara BioCapital is a vote of confidence. However, the dilution from new shares and warrants, and the contingent nature of warrant expiration on clinical trial data, introduce some risk and future uncertainty.

Positives

• VTV Therapeutics successfully secured $25.0 million in new capital through a private placement, strengthening its financial position.
• The participation of institutional accredited investors like Samsara BioCapital indicates confidence in the company's prospects and ongoing clinical development.
• The Registration Rights Agreement facilitates future liquidity for investors, potentially making the investment more attractive and supporting future capital access.

Negatives

• The issuance of new shares and the potential exercise of warrants will result in dilution for existing shareholders.
• The exercise price of Common Warrants ($22.71 or $22.70) is significantly higher than the unit purchase price ($15.265 or $15.255), suggesting a premium for future upside that may not materialize.

Risks

• Dilution Risk: The issuance of new shares and the potential exercise of warrants will dilute the ownership percentage of existing shareholders.
• Warrant Exercise Contingency: The expiration of Common Warrants is tied to the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial, introducing clinical trial risk and uncertainty regarding the warrants' value.
• Beneficial Ownership Blockers: Warrants cannot be exercised to the extent that, following exercise, Samsara LP, together with its affiliates, would own more than 9.99% of the Class A common stock outstanding, which could limit the ability of large investors to fully convert their holdings.

Future Outlook

The filing indicates that the final closing of the private placement is contemplated to occur within 20 calendar days of the initial closing. The Common Warrants' expiration is tied to the announcement of positive top-line data from the Issuer's ongoing CATT1 clinical trial, suggesting future milestones related to clinical development. The Issuer is also committed to filing a shelf registration statement for resale of the securities, aiming for effectiveness within 60-90 days after closing.

Industry Context

This private placement provides capital to VTV Therapeutics, a biotechnology company, which is common for companies in the clinical development stage to fund ongoing research and trials. The involvement of a specialized biotech investor like Samsara BioCapital suggests a strategic investment in the life sciences sector, where capital raises are frequent to support long development cycles and high R&D costs. The CATT1 clinical trial mentioned for warrant expiration indicates the company's focus on drug development, a high-risk, high-reward area within the industry.

Comparison to Industry Standards

• The private placement structure, involving common stock, pre-funded warrants, and common warrants, is a standard mechanism for biotech companies to raise capital while managing immediate dilution and offering upside potential to investors.
• The 9.99% beneficial ownership blocker is a common provision in such agreements to avoid triggering certain regulatory thresholds or shareholder rights plan provisions, aligning with industry best practices for managing ownership concentration.
• Tying warrant expiration to clinical trial data (CATT1) is a typical incentive structure in the biotech industry, aligning investor interests with key R&D milestones and providing a clear catalyst for potential warrant exercise.

Corporate Governance

Related Party Transactions

• Samsara LP and Samsara Opportunity Fund, L.P. are under common control, and both participated in the private placement.
• Dr. Srinivas Akkaraju is the managing member of the general partner of both Samsara BioCapital GP, LLC (general partner of Samsara LP) and Samsara Opportunity Fund, indicating his involvement in the investment decisions for both entities in this transaction with VTV Therapeutics.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new shares and warrants, but the capital raise strengthens the company's financial position, potentially supporting future growth and clinical development.
• Investors (Samsara BioCapital funds): Gain significant equity and warrant positions in VTV Therapeutics, with registration rights to facilitate future liquidity, aligning their interests with the company's long-term success.
• Company (VTV Therapeutics): Receives $25.0 million in capital to fund operations, research, and development, particularly the CATT1 clinical trial, which is crucial for its strategic objectives.

Next Steps

• Final closing of the August 2025 Private Placement, contemplated within 20 calendar days of September 3, 2025.
• Issuer to file a shelf registration statement with the SEC covering the resale of the Registrable Securities on or prior to thirty (30) days following the closing of the August 2025 Private Placement.
• Issuer to use commercially reasonable efforts to have the registration statement declared effective as soon as practicable, but no later than sixty (60) days after the closing (or ninety (90) days if the SEC reviews).
• Issuer to keep the registration statement effective until all Registrable Securities have been sold, can be sold without Rule 144 restriction, or three years after initial effectiveness.
• Ongoing CATT1 clinical trial, with positive top-line data potentially impacting Common Warrant expiration.

Key Dates

Recommendation

The successful $25 million private placement provides VTV Therapeutics with crucial capital, which is a positive development for its ongoing operations and clinical programs, particularly the CATT1 trial. The participation of a specialized biotech investor like Samsara BioCapital indicates a degree of confidence in the company's long-term potential. However, the substantial issuance of new shares and warrants will lead to significant dilution for existing shareholders. While the capital infusion is beneficial, the company remains in a clinical development stage, inherently carrying high risks associated with trial outcomes. The warrant terms, including their expiration tied to CATT1 data, highlight the speculative nature of the investment. Therefore, a 'hold' recommendation is appropriate, acknowledging the strengthened financial position while remaining cautious due to dilution and ongoing clinical development risks. Investors should monitor clinical trial progress and future financial results closely.

Keywords

VTV Therapeutics, Private Placement, Samsara BioCapital, SEC Filing, Schedule 13D/A, Common Stock, Warrants, Pre-Funded Warrants, Capital Raise, Biotechnology, Clinical Trial, CATT1